Mineralys Therapeutics, Inc. (MLYS)

13.00 -0.15 (-1.14%) At close: 04:00PM EDT

Mineralys Therapeutics, Inc.

150 N. Radnor Chester Rd.
Suite F200
Radnor, PA 19087
United States
888 378 6240
https://mineralystx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 28

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.	Founder & Executive Chairman	69.33k	N/A	1977
Mr. Jon Congleton	CEO & Director	775.77k	N/A	1963
Mr. Adam Scott Levy	CFO & Secretary	655.58k	N/A	1978
Dr. David M. Rodman M.D.	Chief Medical Officer	726.95k	N/A	1955
Ms. Cindy Berejikian	Executive Vice President of Operations	N/A	N/A	N/A
Ms. Sarah Foster	Vice President of Human Resources	N/A	N/A	N/A
Dr. Robert McKean Ph.D.	Senior Vice President of CMC	N/A	N/A	N/A
Ms. Danielle Bradbury	Senior Vice President of Quality Assurance	N/A	N/A	N/A
Mr. Jeffrey N. Fellows	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Ms. Jessica Ibbitson	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Corporate governance

Mineralys Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.